Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 6, 2002, Pages 465-472

  Thomas, James P ^a   Tutsch, Kendra D ^a   Cleary, James F ^a   Bailey, Howard H ^a   Arzoomanian, Rhoda ^a   Alberti, Dona ^a   Simon, Kris ^a   Feierabend, Chris ^a   Binger, Kimberly ^a   Marnocha, Rebecca ^a   Dresen, Amy ^a   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Flavopiridol; Pharmacokinetics; Phase I

Indexed keywords

COLESTYRAMINE; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PAIN; CELL CYCLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INFUSION; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HALF LIFE TIME; HEART ATRIUM FIBRILLATION; HUMAN; LUNG TOXICITY; LYMPHOMA; MALAISE; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; ORTHOSTATIC HYPOTENSION; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEX DIFFERENCE; SOLID TUMOR; STEADY STATE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FLAVONOIDS; FLOW CYTOMETRY; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PIPERIDINES; SAFETY; TREATMENT OUTCOME;

EID: 0036450831     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0527-2     Document Type: Article

References (22)

1. Rao RN (1996) Targets for cancer therapy in the cell cycle pathway. Curr Opin Oncol 8:516-524
2. Maik RG, Kattice SL, Bhat SV, Alreja B, de Souza NJ, Rupp RH (1988) An anti-inflammatory cum immunomodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: Isolation, structure and total synthesis. Tetrahedron 44:2081-2086
3. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E (1992) Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84:1736-1740
4. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, Losiewicz MD, Pommier Y, Sausville EA, Send-erowicz AM (1998) Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91:458-465
5. Schwartz GK, Farsi K, Maslak P, Kelsen DP, Spriggs D (1997) Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 3:1467-1472
6. Bible KC, Kaufman SH (1996) Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56:4856-4861
7. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, Greene JF, Koss W, Morgan CD, Stinson SF, Siford TJ, Alvord WG, Klabansky RL, Sausville EA (1998) Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91:2482-2490
8. Worland PJ, Kaur G, Stetler-Stevenson M (1993) Alteration of the phosphorylation state or p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem Pharmacol 46:1831-1840.
9. Losiewicz MD, Carlson BA, Kaur G, Sausville E, Worland PJ (1994) Potent Inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 201:589-595
10. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973-2978
11. Filgueira de Azevedo W, Mueller-Dieckmann HJ, Schulze-Gahmen U, et al (1996) Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci U S A 93:2735-2740
12. Hagiwara M, Inoue S, Tanaka T, Nunoki K, Ito M, Hidaka H (1988) Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Biochem Pharmacol 37:2987-2992
13. Drees M, Dengler WA, Roth T, Labonte H, Mayo J, Malspeis L, Grever M, Sausville EA, Fiebig HH (1997) Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 3:273-279
14. Bible KC, Kaufman SH (1997) Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents - The importance of sequence of administration. Cancer Res 57:3375-3380
15. Sedlacek H, Czech J, Naik R, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz AM, Sausville EA (1996) Flavopiridol (L86-8275; NSC 649890) a new kinase inhibitor for tumor therapy. Int J Oncol 9:1143-1168
16. Wang-Weigun A, Vincent DL, Early RJ, Weems CW (1994) The quantification of phytoestrogens in fresh plant materials by reversed-phase HPLC. Acta Botanica Yunnanica 16:424-430
17. Stinson SF, Hill K, Silford TJ, Phillips LR, Daw TW (1998) Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection. Cancer Chemother Pharmacol 42:261-265
18. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villaba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986-2999
19. Kelland LR (2000) Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status. Expert Opin Investig Drugs 9:2903-2911
20. Kahn ME, Senderowicz A, Sausville EA, Barrett KE (2001) Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol. Clin Cancer Res 7:343-349
21. Innocenti F, Stadler WM, Iyer L, Ramirez J, Vokes EE, Ratain MJ (2000) Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res 6:3400-3405
22. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, Werner J, Perkins P, Stoltz M, Kelsen D (2001) Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 19:1985-1992